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1. Introduction
DC are key regulators of immunity in view of the fact that they are involved in immune re‐
sponses against infectious diseases, allergy and cancer [1, 2]. Ralph Steinman was awarded
the Nobel Prize for Medicine 2011 for DC discovery in 1973 [3]. Steinman and Cohn [3] de‐
scribed a novel cell type in mouse spleen, which they named ´dendritic cell´ due to their
tree-like shape. The major function of DC is the induction of adaptive immunity in the
LN.Yet, DC can also interact with innate immune cells, for instance natural killer (NK) and
NKT cells [1, 4].
Upon entry of HIV into the host, the virus has to be transported from mucosal surfaces to
lymphatic tissues, where it is transmitted to its primary targets, CD4+ T lymphocytes. This
process is thought to be contrived by DC.
DC thereby play critical roles during HIV and SIV (simian immunodeficiency virus) infection.
The skin and mucosa are composed of two compartments, the epidermis and the dermis
(skin) or stratified squamous epithelium and lamina propria (mucosa), each containing a
major subset of DC - Langerhans cells (LC) reside in the suprabasal layers of the epidermis
and epithelia [5], while dermal/interstitial DC are distributed throughout the connective tis‐
sue of the dermis [6, 7].
Both subsets represent immature DC that are very efficient in Ag uptake and processing. As
immature DC (iDC), they reside in peripheral tissue, which they survey for invading patho‐
gens. Upon encounter with antigen (Ag), DC mature (mDC) and migrate to the draining
lymph nodes (LN). They pass through different maturation stages, which enable them to
fulfill specific tasks such as the uptake, the processing and the presentation of Ag on major
histocompatiblity complex (MHC) molecules to naïve T cells. In the T cell area of lymphatic
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tissue the mature DC stimulate Ag-specific CD4+ and CD8+ T cells to proliferate and develop
effector function, such as cytokine production and cytotoxic activity. Effector T cells are re‐
cruited to inflamed peripheral tissue and participate in the elimination of pathogens and in‐
fected cells. This very particular life cycle illustrates why DC are called the ´sentinels of the
immune system´ [8].
In humans, different DC subsets have been identified in blood, spleen and skin, but little is
known respecting resident and migratory DC in human LN. This book chapter will review
the major DC subsets found in humans and their role in HIV-pathogenesis. If data are avail‐
able, also the role of the viral opsonization pattern and its impact on DC interaction will be
discussed.
2. DC subsets and their role in HIV infection
DC are divided into two main groups: conventional myeloid DC (cDC) and non-convention‐
al plasmacytoid DC (pDC) (Figure 1). As recently described byDoulatov et al. (2010) [9], hu‐
man multi-lymphoid progenitors can bring forth all lymphoid cell types, including
monocytes, macrophages and DC. Nonetheless, most DC in steady-state emerge from a
common myeloid progenitor [10]. DC areheterogenous subtypes with distinct functions,
properties and localization [11]. DC progenitors migrate from the bone-marrow through the
blood to lymphoid organs and peripheral tissues. There, they give rise to different cDC sub‐
sets (Figure 1). LC display an exception within the cDC group since they maintain in the epi‐
dermis independent on circulating precursors [12]. Within cDC, migratory and lymphoid-
resident DC are distinguished: migratory DC travel from peripheral tissues to lymphoid
organs, whereas lymphoid-resident DC populate lymphoid organs during their whole life-
span and lack the migratory function. In humans cDC comprise Langerhans Cells (LC), der‐
mal DC (CD103+ and CD103-), BDCA1+ (CD1c)- and BDCA3+ (CD141) DC, and the recently
described CD56+ DC (Figure 1). They are localized in the skin, secondary lymphoid organs
(spleen, tonsils) and blood. pDC develop in the bone-marrow and then they reside in lym‐
phoid organs [13]. HLA-DR+CD123+pDC express BDCA2 and this cell subset is found in
blood, secondary lymphoid organs as well as peripheral tissues, e.g. skin or lungs (Figure 1).
The cDC subtypes and pDC express a different receptor repertoir and comprise distinct
functions with respect to HIV spread, antiviral activity and transmission, which is reviewed
below and shown in Figure 1 (Table adapted from Altfeld et al., [14]). Both cell types are
resident in lymphoid tissues in the steady state, but during an inflammatory response, pDC
and cDC are actively recruited to these tissues [15-17].
2.1. cDC
2.1.1. LC and HIV
LC survey the basal  and suprabasal  layers  of  the stratified squamous epithelium of  the
skin and oral and ano-genital mucosa for invading pathogens [18-21].  Due to their ideal
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localization  in  mucosal  tissues  and  their  long  dendrites  to  efficiently  capture  Ag,  they
comprise the first  line defense against mucosal infections.  After Ag acquisition, LC start
to  mature,  as  represented  by  up-regulation  of  co-stimulatory  molecules  (CD80,  CD86,
CD40), MHC class I and II molecules, CD83 and CCR7 and down-regulation of Langerin
and E-cadherin [22].
Due to CCR7 up-regulation, the mature LC migrate to the LN along a CCL19 and CCL21-leu
(leucine isoform of CCL21) gradient to efficiently prime T cells there [23]. Beside initiating
an effective adaptive immune response, LC were illustrated by DeWitte et al. [24, 25] to also
have important functions with respect to innate immune responses. Beside a specific set of
TLRs (TLR2, 3, 5) and high expression of CD1a, LC express Langerin and contain Birbeck
granules that might be crucial to their innate function [21, 26-29] (Figure 1). The C-type lec‐
tin Langerin interacts with non-opsonized HIV-1 (Figure 2) and other pathogens such as
fungi and bacteria, via fucose or mannose residues. Thereby degradation of HIV-1 in Bir‐
beck granules is promoted and HIV-1 dissemination is limited [24].
Figure 1. DC-subsets and functions during HIV-infection (Table adapted from Altfeld et al., 2011; CD56+ DC added).
HIV co-localizes with Langerin in LC to high extend as shown by confocal microscopic analyses (co-localization: yel‐
low). CD1a+ LC were isolated from human skin, incubated with HIV for 2 hrs, fixed and permeabilized with Cytofix/-
perm (BD Biosciences). The cells were then stained using an anti-human Langerin-PE mAb (red, Dendritics) and the
anti-HIV-Ab KC57-FITC ((green, Beckman Coulter). The nucleus was stained using DRAQ5TM (blue, Invitrogen) (Posch et
al., unpublished).
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 Figure 2. Co-localization of HIV and Langerin on CD1a+ Langerhans Cells isolated from human skin
Early investigations of HIV-LC interactions illustrated that LC are productively infected by
HIV and that they efficiently transmit the virus to T cells [30-32]. These results suggested
that HIV take advantage of the antigen-capturing properties of LC to reach the T cell zone in
the lymphatic tissues and via this route, HIV can establish a productive infection of the host.
However, in vivo only low percentages of LC are infected and despite abundant expression
of the primary HIV-receptor CD4 and the chemokine co-receptor CCR5, high HIV-1 concen‐
trations are required to infect LC in vitro [31, 32]. As shown by Wu and KewalRemani [33]
the percentages to acquire HIV-1 after heterosexual contact with an HIV-positive individual
are between 0.01 to 0.1%, which might be due to a restriction by LC.
Engagement of Langerin trimers on the surface of LC induces formation of Birbeck granules,
which are part of the endosomal recycling system and uniquely found in LC (Figure 3, low‐
er right panel) [34]. Upon capture of mycobacterial lipoproteins by Langerin, these were ex‐
posed to CD1a molecules in Birbeck granules [35], which suggests that Birbeck granule
formation displays a non-classical antigen processing pathway [20]. Also HIV-1 attaches to
Langerin on LC and is subsequently routed to Birbeck granules, which points to a role of the
granules with respect to degradation of viruses.
Studies by Gejitenbeek´s laboratory [24] showed that under homeostatic conditions, Lan‐
gerin expressed on LC and acts as restriction factor for HIV infection. They demonstrated
that, if HIV-gp120 attaches to Langerin, the viral particle is internalized and subsequently
degraded in Birbeck granules. Thus, LC are protected from infection with incoming, non-
opsonized HIV particles and HIV-1 is not disseminated throughout the host [24]. The rap‐
id  internalization  of  HIV-1  into  LC  by  Langerin  impedes  interactions  and  subsequent
fusion with CD4 and CCR5 and also prevents transmission to the main target cells of the
virus,  CD4+  T  cells.  Thereby,  Langerin  acts  as  a  protective  anti-HIV  barrier  during  the
first  steps  of  HIV-1  infection,  if  the  virus  is  non-opsonized  and  if  sexually  transmitted
pathogens are lacking.
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As demonstrated, if the host system is facing other sexually transmitted infections, the anti-
HIV-1-barrier of LC is abrogated and HIV-1 transfer to susceptible CD4+ T cells is promoted
[20, 36, 37]. Pathogens, such as Candida or Neisseria, directly interact with Langerin and
compete with HIV-1-binding. Additional factors explaining the by-passing of the anti-
HIV-1-barrier function of Langerin are that:
• by high viral loads the receptor becomes saturated,
• infections, e.g. Herpes simplex virus infection, down-regulate Langerin surface expres‐
sion [20],
• the HIV-1 entry receptors CD4 and CCR5 are up-regulated during additional sexually
transmitted infections [37],
• or the antiviral function of Langerin is reverted by inflammation-induced TNF-α (tumor-
necrosis-factor α) production due to Candida albicans or Neisseria gonorrhoea [36].
These observations allow to conclude that during acute co-infection the anti-viral function of
LC is significantly decreased.
Not only acute co-infection, but also opsonization of HIV with either complement fragments
or specific Abs might result in reduction or abolishment of the anti-viral function mediated
by Langerin (Wilflingseder and Posch, unpublished data). Upon entry of viruses into the body,
immediate non-specific immune responses are triggered and within a short time the innate
immune system is completely activated. During acute infection multiple humoral and cellu‐
lar players, including cytokines, complement, acute-phase proteins, DC, macrophages, and
natural killer (NK) cells, that co-operate to generate an efficient defense against infection, are
activated. HIV-1 spontaneously triggers the complement system also in absence of specific
Abs by interactions of gp41 with C1q [38-41]. Due to regulators of complement activation
(RCAs) in the viral surface, HIV-1 is very efficiently protected against virolysis, which nor‐
mally occurs due to MAC (membrane attack complex) formation and destruction of patho‐
gens or infected cells. The incorporation of RCAs in the viral surface acts as protection
mechanism and results in opsonization of HIV-1 with complement C3 fragments at the very
initial steps following viral entry. After seroconversion, when HIV-1-specific Abs are estab‐
lished, the virus additionally is opsonized with specific IgGs. The different coating patterns
of the virus change the receptor used on DC due to the density of complement fragments or
Abs on the viral surface [42]. The C-type lectin-virus interaction becomes rather unimpor‐
tant if the virus is opsonized and is substituted by complement or Fc receptor-virus interac‐
tions as already demonstrated using dermal DC [42]. After LC incubation using
complement-opsonized HIV-1, we found that not only sexually transmitted diseases abro‐
gate the antiviral barrier mediated via Langerin but also opsonization of HIV-1 (Wilflingseder
and Posch, unpublished data).
In summary, during acute co-infection or by opsonization with complement fragments or
Abs, the anti-viral function of LC is significantly reduced due to competition for Langerin or
different receptor utilization. This facilitates HIV-1 infection of LC via CD4 and CCR5, intra‐
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cellular uptake of the virus (Figure 3) and promotion of HIV-1 transfer to its targets, CD4+ T
cells.
On the other hand LC were implicated in establishment of infection due to their location in
the foreskin and due to compelling evidence that male circumcision efficiently reduces the
risk to become infected with HIV-1 [43]. It was furthermore shown in vivo in highly HIV-1-
exposed but (IgG) seronegative individuals, that gp41-specific IgA Abs efficiently blocked
transfer of sexually transmitted HIV-1 [44-46]. A very recent study by Tudor et al. [46] illus‐
trated that monomeric 2F5 IgA2 bound to gp41 MPER (membrane proximal external region)
and free virus with greater efficiency than IgG1 and interferred with the initial HIV-1 trans‐
mission via Langerhans Cells. 2F5 IgA2 and IgG1 monomers blocked HIV-1 transcytosis in
monostratified or multilayered epithelia as well as in rectal tissue [46, 47]. These Abs de‐
creased infection of CD4+ T cells and transfer from LC to autologous CD4+ T cells [46]. The
2F5 IgA2 monomer inhibited virus transcytosis and CD4+ T cell infection more efficiently,
while the 2F5 IgG1 monomer was superior in blocking the LC-CD4+ T cell transmission. A
synergistic effect of both, 2F5 IgA2 and IgG1, was observed with respect to LC-CD4+ T cell
transmission and decrease of CD4+ T cell infection [46].
2.1.2. Dermal DC and HIV
Along with LC, HIV-1 firstly attaches to dermal (interstitial) DC upon entry at mucosal sur‐
faces (Figure 1). Dermal DC are underlying the epithelium, do not contain Birbeck granules
and express heterogenous amounts of CD1a [48].
Interstitial DC are localized in the dermis and oral, vaginal and colonic lamina propria [6,
49-52]. They are characterized by the expression of CD11c, high expression of various C-
type lectin receptors (Langerin on CD103+ DC, DC-SIGN on CD103- DC, DEC-205 on both
subsets), TLR2, 3, 4 and 5 and they secrete various cytokines upon pathogenic stimulation
(Figure 1). Since there are only 2 studies available on human CD103+ DC and SIV [53, 54],
the following chapter refers to CD103-, DC-SIGN+ dermal DC.
In vitro experiments showed that DC efficiently capture HIV-1 or SIV, independent on the
maturation status of the cells (Figure 3 and [55]) and subsequently transfer the virus to CD4+
T cells, which initiates a vigorous infection [41, 42, 56, 57]. These experiments imply that in
vivo HIV exploits DC at mucosal sites as shuttles to CD4+ T cells in the LN, but the exact
events with respect to virus spread from mucosal sites to LN have not been enlightened yet.
Thereby, DC seem to play a significant role in the spread of infection as well as in the induc‐
tion of antiviral immunity.
As shown in Figure 3, dermal DC (left panel) and LC (right panel), which emigrated from
whole skin explants, take up variable amounts of HIV-1 particles. As demonstrated by
Frank et al. [55], human and macaque DC interacted similarly with SIV and ample amounts
of virus were captured by DC. Transmission electron microscopic analyses revealed that
iDC, which are endocytically highly active, captured few viral particles near the periphery
of the membrane, while mDC, which down-regulate the endocytic capacity, retained high
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amounts of virions in large vesicular compartments deeper within DC [55]. This points to a
diverse entry and handling of virions within iDC and mDC.
Figure 3. Uptake of HIV into dendritic cells from human skin. Dendritic cells emigrated from whole skin explants were
incubated with HIV for 2h and then fixed and embedded for transmission electron microscopy. Variable amounts of
viral particles are taken up by dermal dendritic cells (left panels) and epidermal Langerhans cells (right panels). Lower
panels show higher magnifications of membrane-enclosed virus particles in a dermal dendritic cell (left panel; some
viruses marked with red/black). In a Langerhans cell (lower right panel) viruses can be seen docking onto the surface
membrane (right asterisk) and already taken up into vesicular structures (left asterisk). A Birbeck granule is depicted in
the inset as the identifying structure for Langerhans cells. N, nucleus.(Photos courtesy of Hella Stössel and Nikolaus
Romani).
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Beside the different handling of HIV-1 or SIV within iDC and mDC, opsonization of the vi‐
rus with either complement fragments and/or Abs significantly affects the binding mecha‐
nism, internalization and infection of DC as well as their T cell stimulatory capacity [41, 42,
58]. As shown by Pruenster et al. [42], the complement cloud around the virus significantly
blocked the accessibility of gp120 and therefore interfered with C-type lectin interaction.
Similar amounts of HIV-1 bound to the surface of DC independent on the opsonization pat‐
tern of the virus (Pruenster et al., 2005). The attachment of the differentially opsonized
HIV-1-preparations was found to be specific (Figure 4 [Wilflingseder and Posch, unpublished
data]), since pre-incubation of the DC with blocking Abs against human DC-SIGN, CD11b
(CR3-α chain) or CD32 (FcγRII) particularly blocked the interactions with the corresponding
virus preparations:
• blocking α-DC-SIGN mAb inhibited interaction with non-opsonized HIV-1 (Figure 4,
HIV),
• blocking α-CR3mAb (TMG6.5) significantly interferred with binding of complement-
opsonized HIV (HIV-C) to DC (Fig.4, HIV-C) and
• blocking α-CD32mAb (AT10) inhibited binding of Ab-opsonized HIV-1 (Figure 4, HIV-
Ig).
Additionally, we found variations respecting infection of DC with differentially opsonized
HIV-1 preparations [41]. Productive infection of DC and LC with HIV-1 was described to be
relatively inefficient compared to HIV-infection of CD4+ T cells and HIV- or SIV-infected DC
are rarely detected in vivo (rev. in Piguet and Steinman[59]). Our study using non-, comple‐
ment-, complement-Ig- or Ig-opsonized HIV-1 uncovered that complement-opsonization of
HIV-1 significantly enhanced DC-infection compared to non-opsonized HIV [41] and further‐
more acted as an endogenous adjuvans for DC-mediated induction of HIV-specific CTLs [58].
In contrast, HIV-1 coated with specific, non-neutralizing Abs significantly impaired infec‐
tion of and integration in DC and also ´trans´-infection of CD4+ T cells after delayed addition
of T cells [41].
Despite the low-level productive infection of DC, non-opsonized HIV-1 is very efficiently
transmitted to T cells either via de novo (´cis´-transfer) or without (´trans´-)infection [60].
This is also true for Ab-opsonized HIV-1, if CD4+ T cells are added immediately to HIV-ex‐
posed DC [41]. Especially C-type lectins, such as DC-SIGN on dermal DC, were connected
to transmitting HIV-1 to T cells in the LN [60, 61]. Similar to Langerin, DC-SIGN has high
affinity for mannose and fucose structures, but despite sharing this feature these receptors
exert completely different effects and functions regarding pathogen processing. Dermal
CD103- DC express DC-SIGN, which captures low titres of HIV-1 by interaction with the en‐
velope glycoprotein gp120 [62]. By complexing DC-SIGN via gp120, HIV-1 is protected from
degradation within the DC in contrast to Langerin, which promotes degradation of the virus
through Birbeck granules as described above [24, 62]. DC-SIGN-complexed HIV-1 remains
stable and infectious over prolonged periods of time within non-lysosomal acidic organelles
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of DC [62, 63]. Thereby, DC-SIGN efficiently transfers HIV-1 to CD4+ T cells, enhances infec‐
tion in DC-CD4+ T cell co-cultures and facilitates ‘trans’-infection of the T cells [62].
Figure 4. Binding of differentially opsonized HIV (non-opsonized HIV, HIV-C, HIV-Ig) in absence and presence of a
blocking anti-human DC-SIGN, CR3 [CD11b] (TMG6.5) or CD32 (AT-10) antibodies. Binding of non-opsonized HIV was
signficantly decreased in the presence of a blocking anti-DC-SIGN Ab, but not affected by pre-incubation of the cells
with a blocking anti-CR3- or CD32-Ab (white bars). HIV-C-interaction with DC was inhibited using a blocking anti-
CD11b (CR3)-Ab TMG6.5, but not by anti-DC-SIGN or CD32 (grey bars). Binding of IgG-opsonized HIV was inhibited by
using a blocking anti-human CD32, but not DC-SIGN or CD11b-Ab (black bars).
Lastly, the antigen-presenting capacity of DC was also shown to be modulated by the opso‐
nization pattern of the virus [58]. Earlier studies illustrated the role of complement opsoni‐
zation respecting induction of effective CTL responses against viral infections, but the exact
mechanism was not determined [64-66]. The exclusive role of DC in priming naïve CD8+ T
cells in response to exogenous cell-associated as well as endogenously synthesized Ags has
been shown [67, 68]. Endogenously synthesized antigens from DC infected with LCMV
(choriomeningitis virus) mediated strong CTL responses, while macrophages and B cells in‐
fected with LCMV did not induce CTLs [68].
We recently  found that  opsonization  of  retroviral  particles  with  complement  fragments
enhanced the ability of DC to induce CTL responses both in vitro and in vivo [58]. HIV-C-
loaded DC mediated significantly higher CD8+ T cell expansion and signficantly better an‐
tiviral activity than DC exposed to non-opsonized HIV in vitro.  This was further verified
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in  vivo  using  the  murine  Friend virus  model.  These  results  indicated  that  ´complement
acts  as  natural  adjuvant  for  DC-induced expansion  and differentiation  of  specific  CTLs
against retroviruses´ [58].
Additionally, we demonstrated that in contrast to complement opsonization, antibody-coat‐
ing of the viral surface attenuated the CTL-stimulatory capacity of HIV-exposed DC [69]. In
some HIV-1-positive individuals, high levels of antibodies and low levels of complement
fragments coat the HIV-1 surface and therefore we investigated the effects of the non-neu‐
tralizing Abs bound to the surface of HIV-1 on the CTL-stimulatory capacity of DC. We ob‐
served ex vivo and in vitro that DC loaded with IgG-opsonized HIV significantly impaired
the HIV-1-specific CD8+ T cell response compared to the earlier described efficient CD8+ T
cell activation induced by DC exposed to complement-opsonized HIV. These novel modula‐
tory effects of the HIV-1-opsonization pattern on the CTL-activating capacity of DC might
influence future vaccination strategies, since strong transient Ab responses subsequent to
vaccination might weaken the CTL-induction by DC, which has to be considered [69].
Preferential expression of CCR5 on immature LC and DC restricts the transmission of X4-
tropic isolates at the site of infection. Additionally, ex vivo analyses revealed that X4-tropic
HIV replicate worse in DC and LC compared to R5-tropic viruses [31, 70, 71]. The relatively
low susceptibility of DC to HIV-1-infection but efficient transfer of virus to CD4+ T cells was
lately ascribed to an HIV-1 escape mechanism from innate recognition by DC [72, 73]. Manel
et al. [72] showed that if DC by-pass resistance to HIV-1 infection [74, 75], they mature, exert
a type I IFN response as well as adaptive immune responses. More recently, Laguette et al.
[73] described the restriction factor SAMHD1 (SAM domain and HD domain-containing
protein 1) to be responsible for inhibiting HIV-1 replication in DC and other cells of the mye‐
loid lineage by degrading or preventing accumulation of HIV-1 DNA due to a putative nu‐
cleotidase activity. As shown by Lahouassa et al. [76], SAMHD1 depletes the pool of
intracellular dNTPs and thus restricts HIV-1 infection in DC by blocking reverse transcrip‐
tion. These recent important findings respecting a formerly unknown cryptic innate sensor
in DC, SAMHD1, and the induction of an efficient type I IFN and adaptive immune re‐
sponse due to DC infection might pave the way for novel therapeutical approaches to treat
retroviral infections.
2.1.3. Blood DC and HIV
2.1.3.1. BDCA1+ DC, BDCA3+ DC, CD56+ DC and HIV
BDCA1+ myeloid DC can be directly isolated from human blood. This population was de‐
scribed to be reduced in the blood of HIV-infected individuals [76-78]. We found that
BDCA1+ DC exerted a decreased transmission of HIV-1 to autologous CD4+ T cells, when the
virus was opsonized with specific IgGs in contrast to non- or complement-opsonized HIV-1
and when the T cells were added delayed [41]. When CD4+ T cells were immediately added
after washing the differentially loaded DC, the same infection efficiency was observed using
HIV, HIV-C or HIV-Ig [41]. The two-phase transfer of HIV to DC as described above (trans-
infection: by-passing of the virus from endolysosomal compartments, first 24 hrs; cis-infec‐
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tion: ´de novo´ HIV-1-infection of DC before transfer to T cells) was also observable in
BDCA1+ DC, because non- and complement-opsonized HIV-1, which cause productive in‐
fection of DC, efficiently infected autologous CD4+ T cells in short- and long-term co-cul‐
tures. BDCA1+ DC exposed to IgG-opsonized HIV-1, which were not productively infected
by the virus, were not able to promote long-term transfer of HIV-1 to susceptible T cells [41].
BDCA3+ DC represent the human equivalent to mouse CD8α+ DC and they are the major
producers of IFN-λ in response to dsRNA poly I:C [80].As recently described by Dutertre et
al. [81] using an 11-color flow cytometric strategy, circulating BDCA1+ DC and BDCA3+ DC
counts were reduced in 15 viremic, untreated patients compared to 8 HIV-1-positive indi‐
viduals under treatment and 13 healthy donors. By using this method, they illustrated that
both blood DC subsets expressed characteristic lineage markers: BDCA1+ DC expressed
CD14, while particularly BDCA3+ DC displayed CD56 on their surface. BDCA3+ DC were
shown to be more significantly down-modulated in viremic patients compared to controls
[82] and it remains to be investigated by longitudinal studies, if combined antiretroviral
therapy can restore the pool of circulating myeloid BDCA1+ and BDCA3+ DC.
Blood CD56+ DC were recently described by Gruenbacher et al. [83] and comprise inter‐
mediate-sized lymphocytes with an HLA-DRhigh, CD80+ and CD86+ expression profile. Upon
cultivation they acquire DC-like morphology with increased levels of above mentioned sur‐
face markers. Upon stimulation, they are able to efficiently stimulate CD56+γδ T cells, which
results in secretion of IFNγ, TNF-α, and IL-1β [84]. The role of CD56+ DC respecting HIV-1
infection and pathogenesis needs to be further investigated.
2.2. pDC and HIV
Plasmacytoid DC (pDC) (Figure 1) or type 1 IFN-producing dendritic cells are innate im‐
mune cells in blood, which are specialized in releasing massive amounts of IFNα and IFNβ
upon viral challenge, including HIV-1 [83]. They constitute <0.2-0.5% of peripheral blood
mononuclear cells (PBMC) [85] and in humans, pDC express the characteristic surface mark‐
ers BDCA-2 (CD303, CLEC4C) and CD123 along with BDCA4 (CD304, NRP1), but they do
not express CD11c, a marker of myeloid DC, or CD14 [86].
pDCs are key players of the innate immune response in vivo and they can prime adaptive
immunity due to the afore mentioned production of high type I interferon levels, especially
upon exposure to viral products [15, 83]. Upon stimulation with DNA or RNA viruses, they
produce up to 1000-fold higher amounts of type I interferons than other cells [84, 87, 88].
The IFNα production in pDC by viruses represents a two-step process – uptake of viruses
occurs due to recognition of envelope glycoproteins by C-type lectin receptors, e.g. mannose
receptor or BDCA2, but induction of IFNα in fact starts in endosomal compartments by liga‐
tion of TLR9 or TLR7 [89-91]. Pathogenic single-stranded RNA or unmethylated DNA are
mainly recognized by TLR7 and TLR9 expressed inside pDC [92]. Thus, the viruses have to
be ingested by pDC into endosomes and NFkB- and MAPK signals through MyD88 must be
stimulated [93]. Not only viruses, but also virus-infected cells can potently activate IFNα
production from pDC [94]. Once activated, pDCs mature and produce large quantities of
pro-inflammatory and antiviral cytokines [95-97]. pDC respond with high amounts of differ‐
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ent IFNα subsets, IFNβ, IFNκ, IFNλ and IFNω on a wide range of enveloped viruses includ‐
ing HIV-1. They additionally produce pro-inflammatory cytokines TNFα, IFNγ and IL-6 as
well as chemokines CXCL-10, CCL-5 and CCL-4 among others [98]. Thereby, pDC also act
as a linker between innate and adaptive immunity.
Data by Zhou et al. [99] indicate that subsequent to HIV-1 challenge, signaling via TLR7 trig‐
gers autophagy and increased IFNα production from human pDC. The IFNα secretion
mediated by an autophagy-dependent pathway may play an important role for T cell trig‐
gering during HIV-1 pathogenesis.
Beside acting as pro-inflammatory cells, pDC also provide negative regulatory signals and
thus induce tolerance. pDC express IDO (indoleamine 2,3-dioxygenase) and PDL-1 (pro‐
grammed death ligand; 1) which are associated with the negative modulation of T cell re‐
sponses and regulatory T cell induction [100-102].
During acute HIV-1 infection, NK cells are recruited and activated by pDC to the sites of in‐
fection and to LN due to IFNα secretion [103, 104]. IFNα was demonstrated to increase the
perforin levels in NK and CD8+ T cells. At the sites of infection ´DC-editing´ occurs by NK
cells, since activated NK cells delete immature pDC to select for the more immunogenic ma‐
ture pDC [105-108].Beside NK cell recruitment and activation, pDC-secreted IFNα promotes
maturation and migration of other DC subsets. Due to their localization, it is unlikely that
pDC are involved in HIV-1 capture, transport and transmission, but they are supposed to
control HIV-1 in the acute phase of infection due to their immediate antiviral and NK pri‐
ming activity.
Chronic exposure to HIV-1 leads to hyperactivation of pDC resulting in simultaneous type I
IFN secretion and IDO expression. Thus, pDC concurrently exert cytotoxic and suppressive
effects on T cells during chronic HIV-1 infection [109].
HIV-1 infection not only disrupts DC homeostasis within myeloid DC subsets, but also pDC
homeostasis is defective during chronic HIV-1 infection. cDC and pDC are lost from blood,
which correlates with high viral loads and low CD4+ T cell counts [76, 110-113]. Deficiencies
in pDC function were among the earliest observations of immune dysfunction in HIV-1 in‐
fection and some of the earliest studies of the ´natural IFN-α-producing cells´ (i.e. pDC) il‐
lustrated that PBMC from AIDS patients were severely compromised in their ability to
produce IFN-α in vitro after stimulation with the virus.
Cell death and/or a failure of bone marrow progenitors to differentiate into pDC might con‐
tribute to the loss of pDC from blood of chronically infected individuals. In non-pathogenic
models of SIV infection, no depletion of blood pDC was observed [114, 115] and HIV-1-posi‐
tive individuals, who are able to control infection (= long-term non-progressors) were also
shown to have increased numbers of blood pDC [111].In contrast, it was described that dur‐
ing HIV-2 infection, which is highly attenuated compared to HIV-1 infection in humans, al‐
so the numbers of blood pDC is found reduced [116]. Thereby, the exact role of pDC
depletion during HIV infection is not clear yet.
The depletion of cDC from the sites of infection was ascribed to a higher expression of CCR7
on the surface of cDC and a signficantly increased CCL19 expression in LN of SIV-infected
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animals, thus suggesting that inflamed LN lure cDC away from the sites of infection early
during progressive SIV infection [117]. A similar mechanism can be imagined for pDC,
which are recruited to inflamed LN via CXCL9 and E-selectin [16, 118], but the pDC loss
could also be due to direct infection, enhanced apoptosis or CD95 up-regulation [119-123].
Not only pDC numbers are decreased during on-going HIV-1 infection, but also the quality
of the cells is suffering. They exert a reduced ability to migrate towards the CXCR4 ligand
CXCL12 [124], they stimulate Treg cells to dampen HIV-1 immunity and they furthermore
shift the Treg-Th17 balance [125, 126]. So far, interactions of differentially opsonized HIV-1
preparations with pDC has not been investigated.
3. Outlook: Impact of the HIV-1 opsonization pattern on DC function
As follows of investigations on HIV-1 in the last 30 years, antibody responses against the vi‐
rus are not effective and cellular immune responses not powerful enough to suppress or
even control HIV-1. DC, the prime inducers and regulators of immunity and tolerance, are
crucial in designing modern vaccines [127-130]. Therefore, nowadays vaccine science shall
combine established classical vaccine approaches with new attempts based on the expanded
immunological knowledge.
Innate and adaptive immune responses are needed to generate efficient, long-lasting protec‐
tion. Immediate innate responses involve activation of the complement system, ligation of
pattern recognition receptors e.g. TLRs, C-type lectins, activation of NK cells, cDC and pDC,
and type I, II, as well as III interferons. For viral clearance, the optimal balance between
CD4+ and CD8+ T cells is required during the adaptive immune responses. Current HIV-1
vaccination strategies include the use of peptides or monocyte-derived DC exposed to
chemically inactivated HIV-1 and aim in designing a vaccine efficiently inducing both, cellu‐
lar and humoral immune responses [131-133]. So far, disappointing results have been ach‐
ieved in clinical trials targeting either cellular [134, 135] or humoral immunity [136, 137]. The
most prominent AIDS vaccine trial so far was the RV144 in Thailand [138], which evoked
strong, but transient Env-specific CD4+ T cell and Ab responses, but only weak HIV-specific
CD8+ T cell responses [131, 138].
HIV-1 induces immediate responses of the immune system upon entering mucosal surfaces.
There, the complement system constitutes a first line of defense against the virus. Recently,
we illustrated an important role for complement opsonization of retroviruses as an endoge‐
nous adjuvant for DC-mediated CTL-induction [58].
Efficient early CD8+ T cell responses are crucial in controlling HIV-1 replication and their
key role in HIV-1 control is additionally substantiated by association of certain HLA class I
alleles and an improved disease progression [139-141]. In view of our very recent observa‐
tions ([58], [69]), we propose that CD8+ T cells are efficiently primed by DC during acute vi‐
ral infection, particularly by enhanced infection of DC with HIV-C [41]. Thus, more efficient
presentation of endogenously synthesized viral Ags via HLA-ABC [41], and ore efficient
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cross-presentation from incoming complement-opsonized HIV-1 are mediated. In contrast,
Ab-opsonization of HIV-1 weakens the CTL-induction by modulation of DC function and
might influence future vaccination strategies [69].
As shown by Lu et al. [142-144] in vitro and in vivo, DC exposed to chemically (aldrithiol-2,
AT-2)-inactivated HIV or SIV induced a virus-specific CTL response. This response was
strong enough to kill HIV-1-infected CD4+ T cells [142], to control the viral load in SIV-in‐
fected monkeys [143] and HIV-infected individuals [144].. The decrease of the viral load in
the HIV-1-infected patients was associated with a higher amount of HIV-1-gag-specific CD8+
T cells and HIV-1-specific CD4+ T cells.
LC were described to allow more cross-priming of CD8+ T cells, while dermal DC are more
specialized in primingnaive CD4+ T cells [145]. The finding that complement-opsonization of
HIV prior loading of DC significantly enhanced the CD8+ T cell-stimulatory capacity of the
cells in combination with using specific DC subtypes might efficiently improve future vacci‐
nation strategies and there is good reason to address DC of the skin, especially Langerhans
cells, for purposes of vaccination.
A greater understanding of the innate and adaptive processes and the different functions of
DC subsets to HIV-1 infection will lead to development of an effective vaccine.
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